

# Heparanase - Pipeline Review, H1 2020

<https://marketpublishers.com/r/H17AF32C17E1EN.html>

Date: March 2020

Pages: 43

Price: US\$ 3,500.00 (Single User License)

ID: H17AF32C17E1EN

## Abstracts

Heparanase - Pipeline Review, H1 2020

### SUMMARY

According to the recently published report 'Heparanase - Pipeline Review, H1 2020'; Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.

The report 'Heparanase - Pipeline Review, H1 2020' outlays comprehensive information on the Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active

and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology and Immunology which include indications Retinopathy, Breast Cancer, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Refractory Multiple Myeloma, Solid Tumor and Wet (Neovascular/Exudative) Macular Degeneration.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166)

The report reviews Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects

The report assesses Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Overview

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Companies Involved in Therapeutics Development

Beta Therapeutics Pty Ltd

CarboMimetics

HepaRx Ltd

Leadiant Biosciences Inc

Zucero Therapeutics Ltd

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug  
Profiles

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone  
Marrow Transplant Rejection and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-2180 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-30119 - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

pixatimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -

Dormant Products

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -

Discontinued Products

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones

Featured News & Press Releases

Jul 21, 2014: European Patent Office Intention to Grant 'Sulfated Oligosaccharide Derivatives' Patent

Oct 29, 2013: PG545 Phase 1 Cancer Trial Update

Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics

May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001

May 30, 2012: Progen Pharma Obtains Australian Patent For Heparan Sulfate Mimetic Compounds

Sep 20, 2011: Progen Announces Closure Of PG545 Phase Ia Clinical Trial

Oct 14, 2009: New Preclinical Data Confirms PG545 As A Promising Clinical Candidate For Cancer

Apr 14, 2008: Progen Pharmaceuticals Announces presentation Of New Data On PG500 Series Of Compounds At The AACR Meeting In San Diego

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Beta Therapeutics Pty Ltd, H1 2020

Pipeline by CarboMimetics, H1 2020

Pipeline by HepaRx Ltd, H1 2020

Pipeline by Leadiant Biosciences Inc, H1 2020

Pipeline by Zucero Therapeutics Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Beta Therapeutics Pty Ltd

CarboMimetics

HepaRx Ltd

Leadiant Biosciences Inc

Zucero Therapeutics Ltd

## I would like to order

Product name: Heparanase - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/H17AF32C17E1EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H17AF32C17E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970